Molina Healthcare, Inc. (MOH) Securities Class Action Lawsuit Filed [November 18, 2025]

Introduction to Molina Healthcare, Inc. (MOH) Securities Class Action Lawsuit

A securities fraud class action has been filed against Molina Healthcare, Inc. (NYSE: MOH) covering February 5, 2025 through July 23, 2025. Investors allege the company misrepresented its medical cost trend assumptions, concealed a growing mismatch between premium rates and medical costs, and tied near-term growth to unusually low use of behavioral health, pharmacy, and inpatient and outpatient services. They claim Molina repeatedly affirmed 2025 guidance despite these pressures. The story broke open in July 2025, when Molina issued two guidance cuts tied to medical cost pressures across all lines of business and reported weaker second-quarter results. According to the complaint, these reversals harmed investors through losses when the truth surfaced.

Molina Healthcare, Inc. (MOH) Securities Lawsuit Case Details

Case Name: Hindlemann v. Molina Healthcare, Inc., et al.
Case No.: 2:25-cv-09461
Jurisdiction: U.S. District Court, Central District of California
Filed on: October 3, 2025

Molina Healthcare, Inc. (MOH) Company Profile

Molina provides managed healthcare services under Medicaid and Medicare and through state insurance marketplaces. As of June 30, 2025, it served approximately 5.7 million members across 22 states through segments including Medicaid, Medicare, Marketplace, and Other.

Molina Healthcare, Inc. (MOH) Securities Lawsuit Class Period

February 5, 2025–July 23, 2025, inclusive.

All persons and entities that purchased or otherwise acquired Molina securities during the Class Period and who were damaged thereby may be eligible to join the Molina Healthcare, Inc. (MOH) class action lawsuit.

Allegations in the Molina Healthcare, Inc. (MOH) Securities Class Action Lawsuit

The lawsuit targets Molina Healthcare, Inc., its Chief Executive Officer Joseph M. Zubretsky, and its Chief Financial Officer Mark L. Keim. According to the complaint, defendants spoke positively about Molina's earnings trajectory and cost management while assuring investors that long-term financial targets remained intact during the class period.

On February 5, 2025, in a press release, Mr. Zubretsky said he was "very pleased" with 2024 performance, described the company's "solid" earnings growth profile heading into 2025, and expressed confidence in achieving long-term targets. That same day, the company issued 2025 guidance of at least $22.50 in GAAP EPS and at least $24.50 in adjusted EPS, representing expected growth over 2024. During this period, the complaint alleges these statements lacked a reasonable basis given mounting medical cost pressures.

As the year progressed, Molina reiterated its stance. In a press release on April 23, 2025, Mr. Zubretsky stated that first-quarter results reflected "disciplined" medical cost management in an "improving rate environment," calling 2025 earnings and growth "solid" and reaffirming a 13%–15% long-term adjusted EPS growth target. That same day, the company reaffirmed its 2025 outlook, including approximately $42 billion of premium revenue and at least $24.50 of adjusted EPS, signaling stability to the market.

Investors allege a different picture behind the scenes. The complaint asserts defendants failed to disclose adverse facts about medical cost trend assumptions and a dislocation between premium rates and medical cost trends. It further alleges that near-term growth depended on unusually low utilization of behavioral health, pharmacy, and inpatient and outpatient services, making a guidance cut substantially likely. As a result, the complaint claims the upbeat statements about the business, operations, and prospects were materially misleading.

The Truth Emerges

The truth began to surface on July 7, 2025. Pre-market, Molina issued a press release annoucing preliminary second-quarter 2025 results showing adjusted earnings of approximately $5.50 per share—below prior expectations—due to medical cost pressures across all three lines of business. The company cut full-year 2025 adjusted EPS guidance from at least $24.50 to a range of $21.50 to $22.50. Mr. Zubretsky explained the "short-term earnings pressure" as a "temporary dislocation between premium rates and medical cost trend which has recently accelerated."

Two weeks later, on July 23, 2025, Molina issued a press released reporting second-quarter 2025 GAAP net income of $4.75 per diluted share, an 8% year-over-year decline, and further slashed full-year adjusted earnings guidance to no less than $19.00 per diluted share. The company also reduced full-year GAAP net income guidance by 27% to $912 million, with management citing a "challenging medical cost trend environment." According to the complaint, these reversals contradicted earlier assurances and the repeated reaffirmations of 2025 guidance, including the April 23, 2025 reaffirmation.

Market Reaction

Following the July 7, 2025 preliminary disclosure, Molina’s stock price fell $6.97, or 2.9%, to close at $232.61 per share on unusually heavy trading volume.

After the July 23, 2025 earnings report and deeper guidance reduction, trading volume was again unusually heavy on July 24, 2025, when the stock fell $32.03, or 16.84%, to close at $158.22 per share.

Next Steps

• Submissions for lead plaintiff are due: December 2, 2025.

• The Court will issue its order for lead plaintiff and counsel in the weeks after submissions are due.

• The Court will then consider motion for class certification.

• The Court will later consider a Motion to Dismiss.

To learn if you are eligible for recovery under the MOH securities class action lawsuit, visit the case submission page here.

Disclaimer: This shareholder alert is for informational purposes only and does not constitute legal advice. Consult a qualified attorney for personalized guidance. No specific outcomes are guaranteed.